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Historically pleural infection was thought to be associated with longer survival in thoracic 
malignancies.  The aim of this population-based cohort study was to investigate this hypothesis in 
mesothelioma, using national data from a high incidence country. 
 
Methods 
Case records for all patients with mesothelioma seen in English hospitals between 01/01/2005 and 
31/12/2014 were extracted from Hospital Episode Statistics using International Classification of 
Diseases Tenth Edition (ICD-10) codes.  Episodes of pleural infection were identified.  Linked 
mortality data was obtained from the Office of National Statistics.   
 
The primary outcome was all-cause mortality. The explanatory variable was pleural infection. Cox 
proportional hazards model was used to analyse survival, with pleural infection, chemotherapy and 
thoracic surgery handled as time-variable co-factors. 
 
Results 
Of 22,215 patients with mesothelioma, 512 (2.3%) developed pleural infection at some point in their 
illness.  Overall median survival was 7.0 months (IQR 2.3-16.4).  Pleural infection was associated with 
shorter survival in the immediate post-infection period (up to 30 days – HR 1.81, 95% CI 1.45 to 2.22) 
and longer term (>30 days – HR 1.81, 95% CI 1.63 to 1.99).  Other factors associated with increased 
mortality were age, male gender and being diagnosed as an inpatient.  Receiving chemotherapy and 
being less economically deprived were associated with longer survival. 
  
 




Pleural infection occurred in 2.3% of people with mesothelioma and was associated with shorter 
survival.  This refutes previous reports suggesting pleural infection may be associated with better 














Mesothelioma is an aggressive tumour that usually affects the pleura, although the peritoneum, 
pericardium and tunica vaginalis may be affected.1,2  Treatment options are limited, but several 
novel therapies are under investigation, with immunotherapy of particular interest.3-6  
 
Prior to the modern era of immunotherapy, a more rudimentary approach existed, using bacterial 
products to stimulate immune responses.  In the early 1900s, Coley’s toxin, a mixture of killed 
Streptococcus pyogenes and Serratia marcescens, was used to treat sarcoma, whilst in the 1970s, 
trials were conducted exploring the anti-cancer effects of intra-pleural Bacillus Calmette-Guérin 
(BCG) and Corynebacterium parvum.7-10  Unfortunately, heterogeneous methodologies and high risk 
of bias in all study designs made the results of these trials difficult to interpret.11 
 
Bacteria can also occur in the pleural space due to infection, either arising spontaneously (often in 
association with pneumonia) or iatrogenically following pleural intervention.  Treatment of pleural 
infection consists of draining the infected fluid, providing appropriate antimicrobial cover and 
supporting patients’ nutritional status.12   In approximately one third of patients, however, this initial 
management will fail, and a surgical procedure is required.13   Fortunately the majority of people 
who experience pleural infection make a full recovery, although there is a not-insignificant mortality 
rate of between 10% and 20%, usually related to older patients or those with multiple medical co-
morbidities.13,14   
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Despite the mortality risk associated with pleural infection, historic reports suggested that it was 
associated with longer survival in patients who had undergone lung cancer surgery.15-17  Similarly, an 
observational study reported longer survival in mesothelioma patients with infected indwelling 
pleural catheters, compared with patients with mesothelioma without infection.18  These studies 
hypothesised that bacteria in the pleural space were stimulating protective immune responses, with 
associated anti-cancer activity.  However, patient numbers were small in all four studies, and 
confidence intervals wide, such that any true effect size may have been clinically meaningless.   
 
This study aimed to investigate the hypothesis that pleural infection is associated with longer 
survival in mesothelioma, using national data to ensure accurate and precise results. 
 
Methods 
Study design & data sources 
This was a population-based cohort study using historic data from Hospital Episode Statistics (HES) 
and the Office of National Statistics (ONS).  The research was approved by the Proportionate Review 
Sub-Committee of the National Research Ethics Service (NRES) Committee London – Central 
(14/LO/1258).   
 
Study participants included all patients with mesothelioma who attended an English hospital 
between 01/01/05 and 31/12/14.  Participants were identified from HES, a database containing 
details of every NHS-related activity in England, using the International Classification of Diseases 
Tenth Edition (ICD-10) codes for mesothelioma (C45, C45.0, C45.1, C45.2, C45.7, C45.9).  Episodes of 
pleural infection were identified using ICD-10 codes J86, J86.0 and J86.9.   
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Records were linked to ONS for 01/01/05 to 28/03/16, using individual, pseudonymised patient 
identifiers.  ONS contains death certificates information for all deaths in England and Wales.   
 
Study variables 
The exposure variable was pleural infection.   The primary outcome was survival, defined as date of 
mesothelioma diagnosis to date of death.  Patients with zero survival time and death certificate 
diagnoses of mesothelioma were excluded.    
 
Data on potential confounders were extracted from HES, using ICD-10 and OPCS Classification of 
Interventions and Procedures (OPCS-4) codes.  These included sex, age at diagnosis, disease site 
(pleural; peritoneal; pericardial; other or unspecified), socio-economic status based on index of 
multiple deprivation (IMD) quintile (1=least deprived; 5=most deprived), rural/urban location (urban 
area of population >10000; town or fringe; village; hamlet or isolated dwelling), comorbidities at 
presentation (defined as number of additional diagnostic codes), mode of initial attendance 
(outpatient appointment; inpatient admission; procedure or operation), year of diagnosis (before or 
after 01/01/2008 as this was the year pemetrexed and cisplatin chemotherapy became standard 
care in the UK19), documented asbestos exposure, documented pleural plaques, undergoing a 
biopsy, thoracoscopy (medical or surgical) or pleurodesis (bedside talc slurry or thoracoscopic 
poudrage), number of pleural interventions, average number of hospital episodes per year and 
undergoing chemotherapy, radiotherapy or thoracic surgery.  Thoracic surgical procedures included 
diagnostic surgery, curative or debulking mesothelioma procedures and interventions to control 
pleural fluid, including video-assisted thoracic surgery (VATS) biopsy, extra-pleural pneumonectomy, 
extended pleurectomy/decortication, pleurectomy, pleural stripping and pleural abrasion.  Chemical 
pleurodesis undertaken at VATS was coded within the pleurodesis category.  
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Statistical analysis 
Patient characteristics were summarised using descriptive statistics, stratified by pleural infection.  
Means with 95% confidence intervals (CI), and medians with inter-quartile ranges (IQR) were 
calculated for normal and non-normally distributed continuous data.  Categorical and binary data 
were reported as proportions. Significance tests were performed using t-tests and Kruskal-Wallis 
tests for normal and non-normally distributed data respectively.  χ2 was used for binary, ordinal or 
categorical variables, with Fisher’s exact test employed if the expected frequency in any group was 
less than 10.   The only variable with missing data was socioeconomic status.  A separate ‘missing’ 
category was created for this variable and used in all analyses.   
 
Pleural infection incidence rate was calculated per 1000 person-years.  Because the incidence of 
pleural infection was likely to vary over time, separate rates were calculated for the periods 0-30 
days, 31-90 days and 90+ days post-mesothelioma diagnosis.  Factors associated with pleural 
infection were investigated using Cox proportional hazards models, with time since mesothelioma 
diagnosis as the time axis.  Potential interactions between pre-specified variables (comorbidities, 
age, IMD quintile, number of pleural procedures, average number of hospital attendances per year, 
diagnosed after 2008) were tested using the Mantel Haenszel method.   
 
Median survival was reported for the whole group, and for patients who did and did not experience 
pleural infection.  Kaplan Meier curves were plotted in people with and without pleural infection.  
Median survival was calculated for patients diagnosed before and after 2008, the year that 
pemetrexed and cisplatin chemotherapy became standard care in the UK.   
 
Survival analyses were undertaken using Cox proportional hazards models, having checked the 
validity of the proportional hazards assumption using Schoenfield residuals and visually with “log-
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log” plots.  All variables were included in the adjusted model, regardless of significance on 
univariable testing.  Collinearity of variables was tested using variance inflation factors (VIF), and any 
factors with VIF higher than 5 were removed and the model re-run to evaluate impact.  Because any 
potential hazard associated with pleural infection could only occur after the infection began, and 
due to suspicion that the hazard may change following recovery from infection, pleural infection was 
handled as a time-varying covariable by splitting follow-up into pre-infection, ≤30 days post-infection 
and >30 days post-infection.  Thoracic surgery and chemotherapy were handled similarly, with 
follow-up split at the time of first treatment.  Survival was censored on 28/03/2016.   
 
The primary analysis assessed all-cause mortality, with mesothelioma-specific mortality modelled as 
a secondary analysis, censoring participants who died of other causes on date of death.  The main 
analysis included all patients.  A priori sub-group analysis investigated patients with pleural 
mesothelioma, since pleural infection was likely to be most relevant to these patients.   
 
Results 
22,896 patient records were identified, of whom 22,215 met the inclusion criteria, contributing 
24,809 patient-years in total (Figure 1).    
 
Of 22,215 patients, 81.7% were male, mean age was 71.8 years (range 18-102), and the majority had 
pleural mesothelioma (51.5% pleural, 5.0% peritoneal, 0.4% pericardial, 42.9% not specified).  For 
16,144 patients (72.7%), the first recorded diagnosis of mesothelioma occurred during an inpatient 
admission, whilst 5,216 (23.5%) were diagnosed at operation or procedure, and 855 (3.9%) during an 
outpatient appointment.  The median number of comorbid codes at presentation was 5 (IQR 3-7), 
with essential hypertension (n=6,428; 28.9%), drug, alcohol or tobacco use (n=4,269; 19.2%) and 
ischaemic heart disease (n=3,789; 17.1%) the most frequent. 
 




512 of 22,215 patients (2.3%) developed pleural infection.  The incidence rate was 24.4 per 1000 
patient-years (95% CI 19.2-22.8).  Pleural infection incidence was higher in the first 30 days after 
diagnosis with mesothelioma (170.0 per 1000 patient-years, 95% CI 151.4-190.9), and fell for the 
period 31-90 days (33.9 per 1000 patient-years, 95% CI 27.7-41.4) and 90+ days post-diagnosis (6.5 
cases per 1000 patient-year, 95% CI 5.5-7.7).   
 
Patients with pleural infection were more likely to be male, comorbid and diagnosed as inpatients 
(Table 1).  Pleural drainage, thoracoscopy, thoracic surgery and pleurodesis were more common in 
patients with pleural infection, who underwent more pleural interventions overall and had more 
hospital episodes per year than patients without infection.  Pleural infection occurred more 
frequently in patients with pleural mesothelioma and was less likely in people who received 
chemotherapy.   
 
In multivariable analysis, pleural infection was associated with male gender, number of co-
morbidities, pleural drainage, thoracic surgery and total number of pleural interventions (Table 2).  
Pleural infection was less common in outpatients, non-pleural mesothelioma, patients who 
underwent thoracoscopy, percutaneous biopsy or pleurodesis, and patients who received 
chemotherapy. 
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Table 1 – Characteristics of 22,215 patients with mesothelioma, stratified by pleural infection.  P values 
derived from t-tests, Kruskal-Wallis tests, χ2 test and Fisher’s exact test. IMD – index of multiple 
deprivation; IoM – Isle of Man; IQR – interquartile range; NI – Northern Ireland; SD – standard deviation. 
 
 Pleural infection 
N=512 
No pleural infection 
N=21,703 
p 
Male, n (%) 455 (88.9) 17,686 (81.5) <0.001 
Age, mean (SD) 70.9 (9.83) 71.8 (9.94) 0.044 
IMD quintile, n (%)           



























Rural/urban location, n (%) 
Urban with ≥10,000 population 
Town and Fringe 
Village 
Hamlet or isolated dwelling 



















Mode of initial attendance, n (%) 
Outpatient appointment 
Inpatient admission 













No. of comorbid codes, median (IQR) 5 (4-8) 4 (3-7) <0.001 
Documented asbestos exposure, n (%) 107 (20.9) 3,423 (15.8) 0.002 





















Total no of pleural procedures, median 
(IQR) 
3 (1-4) 1 (0-2) <0.001 
Diagnosed after 2008, n (%) 313 (61.1) 13,216 (60.9) 0.913 
















Average no. of hospital episodes per 
year, median (IQR) 
3.5 (2-5.5) 3 (1.5-5) <0.001 
Treatment received, n (%) 
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Table 2 – Factors associated with pleural infection in 22,215 patients with mesothelioma, from unadjusted 
and adjusted Cox proportional hazards models.  All listed variables were included in the multivariable 
model. CI – confidence interval; HR – Hazard ratio for pleural infection; IMD – Index of multiple deprivation; 
IoM – Isle of Man; IQR – interquartile range; NI – Northern Ireland; SD – standard deviation. 
 
 Unadjusted analysis Adjusted analysis 
 
HR 95% CI p HR 95% CI p 
Male gender 1.91 1.45 to 2.52 <0.001 1.66 1.25 to 2.20 <0.001 
Age at diagnosis                        ≤65 
66 to 70 
71 to75 








0.67 to 1.14 
0.71 to 1.19 
0.82 to 1.38 












0.62 to 1.06 
0.64 to 1.08 
0.71 to 1.23 





















0.59 to 1.02 
0.64 to 1.10 
- 
0.65 to 1.12 
0.62 to 1.06 
















0.59 to 1.02 
0.63 to 1.08 
- 
0.64 to 1.10 
0.58 to 1.01 









Urban ≥10,000 population 
Town and Fringe 
Village 
Hamlet/ isolated dwelling 









1.01 to 1.70 
0.80 to 1.49 
0.71 to 1.83 















0.95 to 1.63 
0.67 to 1.30 
0.65 to 1.68 
















0.01 to 0.25 
- 










0.02 to 0.86 
- 





Diagnosed after 2008 0.98 0.82 to 1.17 0.809 0.83 0.69 to 1.01 0.057 
No. of comorbid codes 1.14 1.11 to 1.17 <0.001 1.13 1.10 to 1.16 <0.001 
Non-pleural mesothelioma 0.67 0.56 to 0.80 <0.001 0.80 0.67 to 0.97 0.021 
Documented asbestos exposure 1.39 1.13 to 1.73 0.002 0.91 0.73 to 1.13 0.385 












3.11 to 4.53 
1.51 to 2.14 
0.89 to 1.31 












1.26 to 1.98 
0.50 to 0.81 
0.62 to 0.93 






Total no. of pleural procedures 1.50 1.44 to 1.56 <0.001 1.51 1.42 to 1.61 <0.001 
Average no. of hospital episodes 
per year 








0.33 to 0.60 








0.44 to 0.83 
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Thoracic surgery 5.14 3.99 to 6.63 <0.001 2.26 1.67 to 3.07 <0.001 
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With regard to pleural infection, there was evidence of interaction between several variables, including 
comorbidity, total number of pleural procedures and average number of hospital episodes per year. 
However, subsequent univariable analyses controlling for the interacting variable did not alter the observed 
associations to any great degree (see Appendix 1).  
 
Survival 
20,380 deaths occurred over 24,809 patient-years.  Censored participants were followed up for 14.9 
months minimum (range 14.9-134.5, median 40.4).  Median survival was 7.0 months (IQR 2.3-16.4), 
increasing to 7.8 months (IQR 2.6-17.2) in patients diagnosed after 2008 (n=13,529).  Median survival was 
6.2 months in patients with pleural infection (IQR 2.6-14.9) compared with 7.0 months (IQR 2.3-16.4) in 
those without (unadjusted HR 1.12, 95% CI 1.02-1.22, p=0.013).  Unadjusted Kaplan Meier survival curves 
are shown in Figure 2.  
 
All-cause mortality was higher after pleural infection, both in the 30-day post-infection period and 30+ days 
post-infection.  This remained the case in the adjusted survival model (Table 3).  Factors associated with all-
cause mortality were age, male gender, being diagnosed as an inpatient, undergoing percutaneous biopsy, 
undergoing a drainage procedure, documented asbestos exposure, pleural plaques and having undergone 
thoracic surgery.  Non-pleural mesothelioma, being diagnosed after 2008, low socioeconomic deprivation, 
undergoing thoracoscopy or pleurodesis and receiving chemotherapy were positive prognostic variables.   
 
The majority of patients died of mesothelioma (18,604/22,215; 84%), consequently the results for 
mesothelioma-specific mortality were similar to the primary analysis (see Appendix 2).  Sub-group analysis 
of patients with pleural mesothelioma did not reveal any differences compared with the main results (see 
Appendix 3). There was no evidence of collinearity between variables in the multivariable survival analysis 
(see Appendix 4). 
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Table 3 – Factors associated with all-cause mortality in 22,215 patients with mesothelioma, from adjusted 
and unadjusted survival models.  All listed variables were included in the multivariable model. CI – 
confidence interval; HR – Hazard ratio for all-cause mortality; IMD – index of multiple deprivation; IoM – 
Isle of Man; IQR – interquartile range; NI – Northern Ireland; SD – standard deviation. 
 
 
 Unadjusted analysis Adjusted analysis* 
 HR 95% CI p HR 95% CI p 
Pleural infection 
Pre-infection/no infection 
First 30 days post-infection 







1.39 to 2.11 











1.47 to 2.22 





Male gender 1.24 1.20 to 1.29 <0.001 1.26 1.21 to 1.30 <0.001 











1.14 to 1.25 
1.33 to 1.45 
1.64 to 1.79 












1.12 to 1.22 
1.28 to 1.40 
1.52 to 1.67 





















0.90 to 0.98 
0.89 to 0.97 
- 
0.94 to 1.02 
0.99 to 1.08 
















0.91 to 0.99 
0.91 to 0.99 
- 
0.93 to 1.02 
0.98 to 1.07 









Urban ≥10,000 population 
Town and Fringe 
Village 
Hamlet/ isolated dwelling 









1.01 to 1.10 
0.94 to 1.04 
0.85 to 0.99 









1.03                         





0.98 to 1.08  
0.96 to 1.07 
0.88 to 1.04 

















2.11 to 2.50 











1.07 to 1.28 





Diagnosed after 2008 0.86 0.84 to 0.89 <0.001 0.87 0.85 to 0.90 <0.001 
No. of comorbid codes 1.02 1.02 to 1.03 <0.001 0.99 0.98 to 0.99 <0.001 
Non-pleural mesothelioma 1.06 1.03 to 1.09 <0.001 0.95 0.92 to 0.98 <0.001 
Documented asbestos exposure 1.05 1.01 to 1.09 0.014 1.07 1.03 to 1.12 <0.001 












0.87 to 0.92 
0.63 to 0.67 
0.89 to 0.95 












1.16 to 1.26 
0.84 to 0.91 
1.03 to 1.11 






Total no. of pleural procedures 0.87 0.86 to 0.87 <0.001 0.87 0.85 to 0.88 <0.001 
Average no. of hospital episodes 
per year 










0.54 to 0.58 
0.53 to 0.70 










0.93 to 0.99 
0.82 to 1.10 
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Discussion 
This large mesothelioma cohort, using population level data allowed the most rigorous examination 
of the relationship between pleural infection and survival to date.  Pleural infection was more likely 
to occur in the first 30 days after diagnosis with mesothelioma and was associated with increased 
mortality.   
 
The hazard associated with pleural infection was similar to that seen in a Canadian study of patients 
with lung cancer and pleural infection.20   Although that study was conducted in the post-operative 
setting, rather than general follow-up, post-operative empyema (or pneumonia or mediastinitis) was 
a negative prognostic factor, with an adjusted hazard ratio of 1.67 (95% confidence interval 1.39–
2.01).   
 
Interpretation 
Causality cannot be determined from this observational study and for several variables the observed 
association may be bi-directional.  For example, although patients who undergo multiple pleural 
interventions are at higher risk of iatrogenic pleural infection, once infection occurs they will also 
require more interventions to manage it.  This interpretation could also apply to the primary 
outcome, i.e. dying patients may be more likely to develop pleural infection, rather than infection 
being implicated in shortening their life.   
 
When interpreting these results, it is important to differentiate between statistical significance and 
clinical meaningfulness.  The large sample size generated high statistical power, with low p values for 
several analyses.  However, p values provide no information on the size of an effect or clinical 
relevance.  For example, although the variable ‘comorbidities’ was associated with a “statistically 
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significant” reduction in mortality, a HR of 0.99 is unlikely to represent a meaningful survival benefit.  
Additionally, the idea of a threshold p value below which a result is “statistically significant” is 
controversial, with many researchers preferring  to interpret absolute p-values as a measure of the 
strength of an association and 95% confidence intervals to evaluate the size and precision of the 
observed association.21  Importantly, the hazard associated with pleural infection in this study was 
both clinically meaningful and statistically strong. 
 
Our results confirm previously reported prognostic factors in mesothelioma.  Male gender and 
increasing age have been repeatedly shown to be associated with shorter survival,2,22,23 whilst being 
diagnosed during an acute or emergency presentation is a poor prognostic indicator in several 
cancer types.24  Socio-economic position is a predictor of outcome in many medical conditions, both 
malignant and non-malignant, although this association has never been demonstrated in MPM.25-27 
In fact, a recent French study showed that socio-economic status was not associated with survival in 
mesothelioma, however a different index was used to determine deprivation and it is plausible that 
the impact of socioeconomic status varies across different healthcare systems.28 
 
Chemotherapy was associated with a small mortality benefit.  This reflects the fact that for several 
years there was no effective chemotherapy for mesothelioma.  Survival outcomes improved 
following the introduction of pemetrexed and cisplatin, however, the mortality benefit remained 
modest, due to the limited efficacy and low response rates associated with current chemotherapy.5 
Regarding other treatments, our results support the British Thoracic Society guidance that 
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Pleural procedures have no disease-modifying ability and the lower mortality associated with these 
interventions in this study is likely to reflect confounding by indication, e.g. patients must be 
sufficiently fit to undergo thoracoscopy, and this fitness determined their subsequent survival.  The 
corollary is that patients in whom thoracoscopy was contra-indicated (e.g. due to frailty) were more 
likely to be investigated via less-invasive pathways, i.e. percutaneous biopsies, thus survival was 
worse in this group.  Similarly, pleurodesis is generally undertaken in patients who are expected to 
live long enough for recurrent fluid to be a problem, whilst patients with shorter life expectancy are 
often treated with recurrent aspirations.  
 
Patients with missing socioeconomic data and those from Scotland/NI/IoM/Channel Islands had 
dramatically better survival outcomes.  Whilst this could represent a genuine result, it is more likely 
that some of these patients were missing data for other variables, e.g. date of death, resulting in 
apparent longer survival.  Post-hoc investigations revealed that patients in these groups were more 
likely to have been right-censored, supporting this theory.  However, patient numbers were small, 
and a sensitivity analysis omitting these patients resulted in near-identical results.   
 
Strengths & limitations 
This study has several strengths, including use of a resource with national coverage which minimised 
selection bias.  The use of standardised coding ensured that participant identification was 
comprehensive.   Compared with national cancer registry data, we identified between 94.3% and 
100% of patients diagnosed with mesothelioma in England each year.29  The number of deaths in 
2006-2014 represented between 91.5% and 98.4% of deaths recorded by the Health and Safety 
Executive for England for those years.30  Finally, 1-year survival rates and the proportion of patients 
who received chemotherapy were comparable to the national lung cancer audit (38.8% vs 43.1% and 
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36.0% vs 36.5% respectively).31  We are confident, therefore, that our results are a reliable 
representation of the mesothelioma population in England during this period.   
 
This is the first study to report the incidence of pleural infection in mesothelioma, and therefore we 
cannot be certain that case identification was comprehensive.  We assume that pleural infection was 
identified as sensitively as mesothelioma, since the same method was used.  Of note, pleural 
infection incidence in the general population is 6-22 per 100,000, significantly lower than the 
incidence observed here.12,32  Pleural infection appears more common in patients with 
mesothelioma, most likely as an iatrogenic phenomenon due to pleural interventions.   
 
The majority of mesothelioma cases in which disease site was not specified were likely to be pleural 
tumours, as globally over 90% of mesothelioma affects the pleura.33  Therefore, although pleural 
infection appeared more prevalent in pleural mesothelioma, a different result may have been seen if 
disease site had been universally recorded.  Additionally, cases where disease site was not specified 
may have been associated with lower data quality in other domains, although the sub-group analysis 
of pleural cases only did not reveal any great differences compared with the main analysis (see 
Appendix 3). 
 
Another strength was the statistical methodology.  Handling infection as a time-varying covariable 
reduced the risk of immortal-time bias, i.e. patients with pleural infection had to live long enough to 
develop pleural infection.  The same is true for chemotherapy and thoracic surgery. 
 
Certain data are not collected in HES and could not be adjusted for.  Specifically, performance status 
and tumour histological type were not available, and this may have introduced confounding as these 
 
Bibby et al, HES cohort  V3.0 08/07/18 Page 20 of 24 
 
are known prognostic factors.  It may be that pleural infection was more likely in patients with worse 
performance status, with the higher mortality related to poor performance status rather than 
infection.  We created the variable “comorbidities” as a surrogate for performance status, however 
we recognise that this approach was imperfect, as performance status is a global measure of 
function that encompasses more than co-existent medical conditions.  Nonetheless, it was 
reassuring that the mortality hazard associated with pleural infection was not greatly affected by 
adjustments for potential confounders, suggesting the effect of confounding was relatively minor, at 
least for the variables for which data was available. 
 
Confounding by indication is the most likely explanation for the observed discrepancy between the 
adjusted and unadjusted HR associated with chemotherapy. Specifically, age and comorbidities are 
often used to determine suitability for chemotherapy treatment and, therefore, once these variables 
were included in the fully adjusted model, the overall survival benefit of chemotherapy was 
attenuated.  
 
Details relating to pleural infection were also unavailable and, importantly, HES contained no 
information on causative organisms.  This is relevant, as different bacterial species elicit differing 
immunological responses.  For example, gram-positive and gram-negative bacteria induce different 
patterns of cytokine release with varying, sometimes opposing, down-stream responses.34,35   
Additionally, some species secrete virulence factors known as superantigens, which bypass classic 
antigen-binding pathways and induce dramatic inflammatory responses.36  It is possible that 
evaluating all aetiologies of pleural infection together may have masked a true effect related to a 
single organism or species.   
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Prospective data collection could overcome some of these limitations, although the study population 
would need to be large.  A multi-centre observational mesothelioma study is underway in the UK 
(ASSESS-meso ISRCTN61861764) with data collection ongoing for the next decade.  Another 
approach could link HES to a third dataset with information on the variables of interest, e.g. the 
National Lung Cancer Audit. 
 
Conclusion 
In this national cohort of mesothelioma patients, pleural infection was associated with higher 30-day 
and long-term mortality.  However, unavailable data for certain prognostic variables may have 
introduced confounding, and the lack of information about bacteria meant that associations 
between individual organisms and survival could not be explored.  Nonetheless, this large, well-
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